Pancreatic Cancer Trial, Recruiting NCT06305728 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06305728
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men and women who are over 18 years old
  • People who have a cyst on their pancreas that has been assessed as high risk and needs to be removed by surgery
  • People who are able to understand and agree to take part in the study by giving informed consent

Who may not be able to join:

  • People who have already been diagnosed with pancreatic cancer
  • People who are currently pregnant or breastfeeding
  • People who are unable or unwilling to have a scan, for example due to anxiety or claustrophobia
  • People who are unable to lie flat or meet the standard requirements for a traditional MRI scan
  • People whose liver is not working well enough, based on blood tests taken within the past 6 weeks — this includes having certain liver-related blood test results that are too high or too low (confirm with trial site)
  • People whose kidneys are not working well enough, based on blood tests taken within the past 6 weeks (confirm with trial site)
  • People with certain heart conditions, including heart failure of a certain severity, poorly controlled high blood pressure, a significant history of abnormal heart rhythm readings, or a heart attack within the past 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kevin Soares, MD, Memorial Sloan Kettering Cancer Center

Phone: 212-639-3195

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 March 2024
Est. completion
4 March 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sensitivity of ImmunoPET to identify presence or absence of adenocarcinoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov